- Home
- OGN vs IMVT Comparison
OGN vs IMVT Comparison
Compare OGN & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGN
- IMVT
- Stock Information
- Founded
- OGN 1923
- IMVT N/A
- Country
- OGN United States
- IMVT United States
- Employees
- OGN N/A
- IMVT N/A
- Industry
- OGN Biotechnology: Pharmaceutical Preparations
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OGN Health Care
- IMVT Health Care
- Exchange
- OGN Nasdaq
- IMVT Nasdaq
- Market Cap
- OGN 4.0B
- IMVT 3.4B
- IPO Year
- OGN N/A
- IMVT N/A
- Fundamental
- Price
- OGN $14.73
- IMVT $16.42
- Analyst Decision
- OGN Hold
- IMVT Strong Buy
- Analyst Count
- OGN 5
- IMVT 11
- Target Price
- OGN $20.80
- IMVT $44.13
- AVG Volume (30 Days)
- OGN 3.8M
- IMVT 2.1M
- Earning Date
- OGN 05-01-2025
- IMVT 02-06-2025
- Dividend Yield
- OGN 7.61%
- IMVT N/A
- EPS Growth
- OGN N/A
- IMVT N/A
- EPS
- OGN 3.33
- IMVT N/A
- Revenue
- OGN $6,403,000,000.00
- IMVT N/A
- Revenue This Year
- OGN N/A
- IMVT $108.88
- Revenue Next Year
- OGN $0.71
- IMVT N/A
- P/E Ratio
- OGN $4.42
- IMVT N/A
- Revenue Growth
- OGN 2.23
- IMVT N/A
- 52 Week Low
- OGN $13.87
- IMVT $14.90
- 52 Week High
- OGN $23.10
- IMVT $34.47
- Technical
- Relative Strength Index (RSI)
- OGN 46.35
- IMVT 37.28
- Support Level
- OGN $14.81
- IMVT $17.49
- Resistance Level
- OGN $14.94
- IMVT $18.96
- Average True Range (ATR)
- OGN 0.52
- IMVT 1.37
- MACD
- OGN -0.08
- IMVT -0.26
- Stochastic Oscillator
- OGN 42.03
- IMVT 27.39
About OGN Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).